Acute hospital, community, and indirect costs of stroke associated with atrial fibrillation: Population-based study

Stroke

Volumn 45, Issue 12, 2014, Pages 3670-3674

  Hannon, Niamh ^a   Daly, Leslie ^b   Murphy, Sean ^a   Smith, Samantha ^c   Hayden, Derek ^a   Chróinín, Danielle Ní ^a   Callaly, Elizabeth ^a   Horgan, Gillian ^a   Sheehan, Órla ^a   Honari, Bahman ^b   Duggan, Joseph ^a   Kyne, Lorraine ^a   Dolan, Eamon ^d   Williams, David ^e   Wiley, Miriam ^c   Kelly, Peter J ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c ECONOMIC AND SOCIAL RESEARCH INSTITUTE   (Ireland)

^d Stroke and Hypertension Unit   (Ireland)

^e BEAUMONT HOSPITAL   (Ireland)

Author keywords

Atrial fibrillation; Healthcare economics and organizations; Prevention and control; Stroke

Indexed keywords

AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMMUNITY CARE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NURSING HOME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANKIN SCALE; RECURRENT DISEASE; SUBARACHNOID HEMORRHAGE; SURVIVAL; TRANSIENT ISCHEMIC ATTACK; TREATMENT PLANNING; COMPLICATION; COST OF ILLNESS; DEMOGRAPHY; ECONOMICS; HOSPITAL; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HOSPITALS; HUMANS; MALE; MIDDLE AGED; RESIDENCE CHARACTERISTICS; STROKE;

EID: 84922481000     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.005960     Document Type: Article

References (27)

1. Hannon N, Sheehan O, Kelly L, Marnane M, Merwick A, Moore A, et al. Stroke associated with atrial fibrillation-incidence and early outcomes in the North Dublin Population Stroke study. Cerebrovasc Dis. 2010;29:43-49.
2. Kimura K, Minematsu K, Yamaguchi T; Japan Multicenter Stroke Investigators' Collaboration (J-MUSIC). Atrial fibrillation as a predictive factor for severe stroke and early death in 15831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry. 2005;76:679-683.
3. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36:1115-1119.
4. Mattle HP. Long-term outcome after stroke due to atrial fibrillation. Cerebrovasc Dis. 2003;16(suppl 1):3-8.
5. Go A, Hylek E, Phillips K, Borowsky LH, Henault LE, Chang Y, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention:the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370-2375.
6. Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. Costeffectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44:1676-1681.
7. Kasmeridis C, Apostolakis S, Ehlers L, Rasmussen LH, Boriani G, Lip GY. Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants. Pharmacoeconomics. 2013;31:971-980.
8. Kamel H, Easton JD, Johnston SC, Kim AS. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology. 2012;79:1428-1434.
9. Kamel H, Johnston SC, Easton JD, Kim AS. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2012;43:881-883.
10. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158:229-234.
11. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care. 2004;10(suppl 14):S451-S458.
12. Brüggenjürgen B, Rossnagel K, Roll S, Andersson FL, Selim D, Müller-Nordhorn J, et al. The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. Value Health. 2007;10:137-143.
13. Ghatnekar O, Glader EL. The effect of atrial fibrillation on stroke-related inpatient costs in Sweden: a 3-year analysis of registry incidence data from 2001. Value Health. 2008;11:862-868.
14. Boccuzzi SJ, Martin J, Stephenson J, Kreilick C, Fernandes J, Beaulieu J, et al. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed. Curr Med Res Opin. 2009;25:2853-2864.
15. Winter Y, Wolfram C, Schaeg M, Reese JP, Oertel WH, Dodel R, et al. Evaluation of costs and outcome in cardioembolic stroke or TIA. J Neurol. 2009;256:954-963.
16. Kelly PJ, Crispino G, Sheehan O, Kelly L, Marnane M, Merwick A, et al. Incidence, event rates, and early outcome of stroke in Dublin, Ireland: the North Dublin Population Stroke study. Stroke. 2012;43:2042-2047.
17. Feigin VL, Carter K. Stroke incidence studies: one step closer to the elusive gold standard? Stroke 2004;35:2045-2047.
18. Coull AJ, Silver LE, Bull LM, Giles MF, Rothwell P. Oxford Vascular (OXVASC) Study. Direct assessment of completeness of ascertainment in a stroke incidence study. Stroke. 2004;35:2041-2045.
19. Camm J, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
20. Smith S, Horgan F, Sexton E, Cowman S, Hickey A, Kelly P, et al. Cost of stroke in Ireland: estimating the annual economic cost of stroke and TIA in Ireland, the Irish Heart Foundation, Dublin 2010. http://www.irishheart. ie/media/pub/strokereports/cosi.pdf. Accessed October 15, 2013.
21. Griswold M, Parmigiani G, Potosky A, Lipscomb J. Analyzing healthcare costs: a comparison of statistical methods motivated by medicare colorectal cancer charges. Biostatistics. 2004;1:1-23.
22. Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda JG, Van Gelder IC. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace. 2011;13:1375-1385.
23. Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. A review of the cost of atrial fibrillation. Value Health. 2012;15:240-248.
24. Cotté FE, Chaize G, Kachaner I, Gaudin AF, Vainchtock A, Durand- Zaleski I. Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France. J Stroke Cerebrovasc Dis. 2014;23:e73-e83.
25. WHO. Preventing chronic diseases: a vital investment. Geneva, Switzerland: World Health Organisation; 2005. http://www.who.int/chp/ chronic-disease-report/en/index.html. Accessed October 19, 2011.
26. Camm J, Lip G, De Caterina R, Savelieva I, Atar D, Hohnloser H, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719-2747.
27. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625-651.